DE602006007967D1 - Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon - Google Patents

Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Info

Publication number
DE602006007967D1
DE602006007967D1 DE602006007967T DE602006007967T DE602006007967D1 DE 602006007967 D1 DE602006007967 D1 DE 602006007967D1 DE 602006007967 T DE602006007967 T DE 602006007967T DE 602006007967 T DE602006007967 T DE 602006007967T DE 602006007967 D1 DE602006007967 D1 DE 602006007967D1
Authority
DE
Germany
Prior art keywords
epitop
muted
joint
applications
chain antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006007967T
Other languages
German (de)
English (en)
Inventor
Beka Solomon
Sara Orgad
Itai Benhar
Ronit Rosenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE602006007967D1 publication Critical patent/DE602006007967D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006007967T 2005-03-25 2006-03-23 Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon Expired - Lifetime DE602006007967D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66496705P 2005-03-25 2005-03-25
US69891905P 2005-07-14 2005-07-14
PCT/IL2006/000372 WO2006100681A2 (en) 2005-03-25 2006-03-23 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Publications (1)

Publication Number Publication Date
DE602006007967D1 true DE602006007967D1 (de) 2009-09-03

Family

ID=36617330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006007967T Expired - Lifetime DE602006007967D1 (de) 2005-03-25 2006-03-23 Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Country Status (6)

Country Link
US (2) US8039594B2 (https=)
EP (1) EP1863846B1 (https=)
JP (1) JP2008533986A (https=)
AT (1) ATE437185T1 (https=)
DE (1) DE602006007967D1 (https=)
WO (1) WO2006100681A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100681A2 (en) 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
AU2007275258A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2573565A1 (en) 2011-09-23 2013-03-27 Gerhard Matthias Kresbach Immune detection method for common epitopes of two or more analytes in samples of complex compositions, device, and kit for enabling said immune detection method
WO2016154246A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
KR20180021080A (ko) 2015-06-19 2018-02-28 에츠코 미야모토 단백질 분해 유도 태그 및 그 용도
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
AU2017361155B2 (en) 2016-11-15 2023-03-30 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
EP3542821A4 (en) 2016-11-15 2020-05-27 Tokyo University of Science Foundation P53 DEGRADATION INDUCTING MOLECULE AND PHARMACEUTICAL COMPOSITION
AU2018269370B2 (en) 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
EP4412650A1 (en) * 2021-10-05 2024-08-14 The Penn State Research Foundation Methods for treating cancers with mutated p53
CA3260982A1 (en) * 2022-07-10 2024-01-18 Mbrace Therapeutics, Inc. Cell-free processes for the production of recombinant antibodies
CN115876993B (zh) * 2022-11-17 2024-10-15 沈阳农业大学 基于生物膜干涉技术检测病原生物凝集素与唾液酸乳糖亲和力方法的建立

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
WO2006100681A2 (en) 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Also Published As

Publication number Publication date
US20110262447A1 (en) 2011-10-27
WO2006100681A3 (en) 2007-05-24
US8207309B2 (en) 2012-06-26
EP1863846B1 (en) 2009-07-22
EP1863846A2 (en) 2007-12-12
US20100074908A1 (en) 2010-03-25
JP2008533986A (ja) 2008-08-28
ATE437185T1 (de) 2009-08-15
US8039594B2 (en) 2011-10-18
WO2006100681A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
EA200701918A1 (ru) Белок липокалин
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
ATE461220T1 (de) Anti-egfr-antikörper
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
ATE424560T1 (de) Marker für neuromyelitis optica
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition